SCHEMBL6778897

SCHEMBL6778897

COC(=O)c1ccc2onc(O)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.53
CA1 P00915 3/20 0.53
CA2 P00918 3/20 0.53
CA7 P43166 3/20 0.53
CA9 Q16790 3/20 0.53
CA14 Q9ULX7 3/20 0.53
XDH P47989 2/20 0.53
HIF1A Q16665 1/20 0.48
LCK P06239 1/20 0.48
KDM4E B2RXH2 4/20 0.47
MAPT P10636 4/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 3/20 0.47
LMNA P02545 2/20 0.47
TP53 P04637 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15660075 0.84 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL30040356 0.84 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL6089113 0.83 MAPT (0.47) CA12CA1CA2CA7CA9
SCHEMBL23535844 0.79 HTR1F (0.50) CA12CA1CA2CA7CA9
SCHEMBL3355075 0.79 MEN1 (0.48) CA12CA1CA2CA7CA9
SCHEMBL30864291 0.79 HTR1F (0.50) CA12CA1CA2CA7CA9
SCHEMBL25353360 0.79 NPC1 (0.56) CA12CA1CA2CA7CA9
SCHEMBL30535719 0.79 NPC1 (0.56) CA12CA1CA2CA7CA9
SCHEMBL5618133 0.76 HIF1A (0.42) CA12CA1CA2CA7CA9
SCHEMBL68516 0.76 CA1 (0.53) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists ANDO KAZUO (JP) 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists GRIN1, GRIN2B, GRIN2A CA12 4192/4885CA1 1488/4885CA2 2007/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.